Evidence & concentration worksheet · Metabolic & Weight Loss
Tirzepatide 30 mg
Evidence supports named, regulated products and indications. A research powder or different vial strength does not inherit the approved product's formulation, reconstitution, storage, or dosing instructions.
Evidence review
Approved dosing is product-specific
Evidence supports named, regulated products and indications. A research powder or different vial strength does not inherit the approved product's formulation, reconstitution, storage, or dosing instructions.
How it works
Tirzepatide is a synthetic peptide medication that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[4][5] Incretins help coordinate insulin release, appetite, and glucose handling after meals, and the approved tirzepatide products are formulated for once-weekly subcutaneous dosing.
In the United States, Mounjaro is FDA-approved for improving glycemic control in adults with type 2 diabetes; Zepbound is approved for chronic weight management in specified adults and for moderate-to-severe obstructive sleep apnea in adults with obesity.[1][2][3] These approvals apply to the named products, presentations, indications, and labels — not to an unverified powder sold as a "research vial."
Benefits & side effects
The SURPASS program evaluated tirzepatide in type 2 diabetes. In SURPASS-2, tirzepatide produced larger mean A1C and weight reductions than semaglutide 1 mg over 40 weeks, with gastrointestinal effects common in both groups.[6] That trial does not compare every semaglutide product or dose.
SURMOUNT-1 reported substantial dose-related weight reductions over 72 weeks in adults with obesity or overweight without diabetes, and SURMOUNT-2 studied adults who also had type 2 diabetes.[7][15] Separate randomized evidence supports the obstructive-sleep-apnea indication, while SURMOUNT-4 found weight regain after randomized withdrawal.[16][17] Claims about anti-aging or performance enhancement are not supported by this trial base.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- U.S. FDA — Mounjaro prescribing information (2026)
- U.S. FDA — Zepbound prescribing information (2026)
- U.S. FDA — FDA approval for tirzepatide in obstructive sleep apnea (2024)
- PubChem — Tirzepatide compound summary (2026)
- Molecular Metabolism — Preclinical pharmacology of the dual GIP/GLP-1 agonist LY3298176 (2018)
- New England Journal of Medicine — Tirzepatide versus semaglutide in type 2 diabetes (2021)
- New England Journal of Medicine — SURMOUNT-1 tirzepatide obesity trial (2022)
- U.S. FDA — Concerns with unapproved GLP-1 drugs used for weight loss (2026)
- Cell Metabolism — Biology of incretin hormones (2006)
- The Lancet — SURMOUNT-2 trial in obesity and type 2 diabetes (2023)
- New England Journal of Medicine — Tirzepatide for obstructive sleep apnea and obesity (2024)
- JAMA — SURMOUNT-4 randomized withdrawal trial (2024)
- U.S. FDA — Proposed exclusion of tirzepatide and semaglutide from the 503B bulks list (2026)